Antibiotic resistance problems with Helicobacter pylori

被引:110
作者
Alarcón, T [1 ]
Domingo, D [1 ]
López-Brea, M [1 ]
机构
[1] Hosp Univ Princesa, Dept Clin Microbiol, Madrid 28006, Spain
关键词
Helicobacter pylori; metronidazole; clarithromycin; resistance; susceptibility methods;
D O I
10.1016/S0924-8579(99)00051-5
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Helicobacter pylori is very susceptible in vitro to most antibiotics, but when they are used in the clinical setting, eradication of the bacteria from the gastric mucosa is not obtained. Dual or triple therapy including two of the following antibiotics: amoxicillin, tetracycline, metronidazole or clarithromycin, plus a proton pump inhibitor, bismuth salt or ranitidine bismuth citrate is the most frequently used. Various in vitro susceptibility methods have been used: disk diffusion, agar dilution and Epsilometer test (E-test). Metronidazole resistance among H. pylori strains is now found worldwide, and resistance rates vary according to the population studied. It is higher in developing than in developed countries and it could reach 80-90% in Africa. The prevalence on clarithromycin resistance is much lower, usually below 10%, although very high values are reported in Peru. Infection with metronidazole- or clarithromycin-resistant H. pylori strains is correlated with treatment failure when using regimens including these antibiotics. (C) 1999 Elsevier Science B.V. and International Society of Chemotherapy. All rights reserved.
引用
收藏
页码:19 / 26
页数:8
相关论文
共 93 条
  • [41] LAMOULIATTE H, 1996, GASTROENTEROLOGY, V110, pA171
  • [42] Lerang F, 1997, AM J GASTROENTEROL, V92, P248
  • [43] Lerang F, 1997, GASTROENTEROLOGY, V112, pA198
  • [44] ONE WEEK ERADICATION REGIMEN FOR HELICOBACTER-PYLORI
    LOGAN, RPH
    GUMMETT, PA
    MISIEWICZ, JJ
    KARIM, QN
    WALKER, MM
    BARON, JH
    [J]. LANCET, 1991, 338 (8777) : 1249 - 1252
  • [45] Study of the combination of ranitidine bismuth citrate and metronidazole against metronidazole-resistant Helicobacter pylori clinical isolates
    López-Brea, M
    Domingo, D
    Sánchez, I
    Prieto, N
    Alarcón, T
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1998, 42 (03) : 309 - 314
  • [46] Evolution of resistance to metronidazole and clarithromycin in Helicobacter pylori clinical isolates from Spain
    LopezBrea, M
    Domingo, D
    Sanchez, I
    Alarcon, T
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1997, 40 (02) : 279 - 281
  • [47] SUSCEPTIBILITY OF HELICOBACTER-PYLORI TO METRONIDAZOLE
    LOPEZBREA, M
    MARTIN, E
    LOPEZLAVID, C
    SANZ, JC
    [J]. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1991, 10 (12) : 1082 - 1083
  • [48] LOPEZBREA M, 1993, ACTA GASTROENTEROL S, V56, P126
  • [49] MARSHALL BJ, 1984, LANCET, V1, P1311
  • [50] Appearance of a metronidazole-resistant Helicobacter pylori strain in an infected-ICR-mouse model and difference in eradication of metronidazole-resistant and -sensitive strains
    Matsumoto, S
    Washizuka, Y
    Matsumoto, Y
    Tawara, S
    Ikeda, F
    Yokota, Y
    Karita, M
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (12) : 2602 - 2605